Cost–effectiveness of catch-up programs in human papillomavirus vaccination

Years of potential life lost and productivity costs because of cancer mortality and for specific cancer sites where human papillomavirus may be a risk factor for carcinogenesis-United States, 2003

(2010) Donatus U. Ekwueme et al.   CANCER

Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection

(2010) Sven-Eric Olsson et al.   Human vaccines & immunotherapeutics

Cost-Effectiveness Analyses of Vaccination Programmes

(2009) Sun-Young Kim et al.   PHARMACOECONOMICS

Effectiveness and Cost Effectiveness of Human Papillomavirus Vaccine

(2009) Fawziah Marra et al.   PHARMACOECONOMICS

Cost of Treatment and QALYs Lost Due to Genital Warts: Data for the Economic Evaluation of HPV Vaccines in the United Kingdom

(2009) Sarah C. Woodhall et al.   SEXUALLY TRANSMITTED DISEASES

Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women

(2009) C K Fairley et al.   SEXUALLY TRANSMITTED INFECTIONS

The economic burden of noncervical human papillomavirus disease in the United States

(2008) Delphine Hu et al.   AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY

The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK

(2008) EJ Dasbach et al.   BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY

Structural differences among cost–effectiveness models of human papillomavirus vaccines

(2008) Ralph P Insinga et al.   Expert Review of Vaccines

Health and Economic Implications of HPV Vaccination in the United States

(2008) Jane J. Kim et al.   NEW ENGLAND JOURNAL OF MEDICINE

Estimation of the impact of genital warts on health-related quality of life

(2008) S Woodhall et al.   SEXUALLY TRANSMITTED INFECTIONS

Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model

(2008) Cara Usher et al.   VACCINE

Evolution of the health economics of cervical cancer vaccination

(2008) Nicole Ferko et al.   VACCINE

Modeling Cervical Cancer Prevention in Developed Countries

(2008) Jane J. Kim et al.   VACCINE

Assessment of the cost–effectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model

(2008) Erik J Dasbach et al.   Expert Review of Pharmacoeconomics & Outcomes Research